Menu

Advisory Memorial Board

Dr. Steven B. Harris

Steven B. Harris, M.D. is Director of Research at Critical Care Research.
 
Steve earned his B.S. degree in chemistry (A.C.S) and his M.D. from the University of Utah. He’s licensed to practice medicine in Utah and California, and has been board-certified in internal medicine and geriatrics. He studied gerontology with Roy Walford, MD, at UCLA.
 
Steve is presently engaged almost full-time in experimental physiology at USDA approved private biomedical animal research institution, Critical Care Research (Rancho Cucamonga, California). This research involves development of resuscitation physiology involving delivery of lipid-soluble drugs to the resuscitated brain (dog model), and also experimental hypothermia induction for resuscitation and cerebral protection using post-resuscitation hypothermic perfluorocarbon lung lavage (also dog model). Some of this research has been published in Resuscitation 50:189-204, 2001.
 
His experience with formulation of microemulsions of lipid soluble drugs for resuscitation has led him to pursue collaborative ventures involving microemulsification technology for delivery of water insoluble drugs and nutrients for animal feed, veterinary and medical applications. He is pursuing patents for microemulsion formulations of CoQ10 and propofol.
 
A key propofol/Solutol HS-15 microemulsion patent has been granted to Steven B. Harris and Nick Huang in Australia (Pat. No. 2005215517), Canada (Pat. No. 2,556,185, etc), China, India, Japan (allowed, not yet issued), Mexico, New Zealand, South Africa, Russia, and Ukraine. Major claims have been allowed (not yet issued) in the U.S. It is pending in several other domains (such as the E.U.). This inexpensive, clear, non-bacterial growth-supporting microemulsion formulation of propofol should eventually replace all existing preparations of this important surgical general anesthetic agent. These patented domains cover half the world’s population. Steve’s team is seeking venture capital. This formulation of propofol has been shown in horses to be equivalent to standard preparations: See pubmed 6948589.
 
Read his LinkedIn profile.